Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial.

RJ, McCrimmon; P, Home; A, Cheng; F, Giorgino; V, Fonseca; E, Souhami; A, Alvarez; P, Picard; J, Rosenstock

doi:10.1111/dom.14825

Public

Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial.

Shared by NobleBlocks on Aug 23, 2022 • 12:00 AM UTC

Authors:

McCrimmon RJ

Home P

Cheng A

Abstract

<h4>Aims</h4>To explore details of the incidence and rates of daytime and nocturnal hypoglycaemia, levels of hypoglycaemia, and relationship to glycated haemoglobin (HbA1c), when comparing iGlarLixi versus premixed biphasic insulin aspart 30 (BIAsp 30) in the SoliMix randomized controlled trial.<h4>...

Subject

Type 2 diabetes

hypoglycaemia

Biasp 30

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!